{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:44:01Z","timestamp":1789404241742,"version":"build-2803163510"},"reference-count":289,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.addr.2026.115793","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T16:27:11Z","timestamp":1770395231000},"page":"115793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["High concentration subcutaneous biological drug products: challenges and advancements"],"prefix":"10.1016","volume":"232","author":[{"given":"Guangli","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikolaj","family":"Milewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogita","family":"Krishnamachari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Peter","family":"Wuelfing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Givand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubi","family":"Burlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Templeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmi","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Buist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0010","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-022-00100-4","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"3","author":"Wang","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.addr.2026.115793_bb0015","unstructured":"1186\/s43556\u2013022\u201300100-4."},{"issue":"7","key":"10.1016\/j.addr.2026.115793_bb0020","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1016\/j.xphs.2021.03.017","article-title":"A review of formulations of commercially available antibodies","volume":"110","author":"Strickley","year":"2021","journal-title":"J. Pharm. Sci. USA"},{"issue":"7","key":"10.1016\/j.addr.2026.115793_bb0025","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1016\/j.xphs.2021.03.017","article-title":"A review of Formulations of Commercially Available Antibodies","volume":"110","author":"Strickley","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0030","first-page":"262","article-title":"US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives","volume":"4","author":"Wang","year":"2021","journal-title":"Antib Ther"},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/NAN.0b013e31824d2271","article-title":"Subcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costs","volume":"35","author":"Dychter","year":"2012","journal-title":"J. Infus. Nurs."},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40271-014-0075-y","article-title":"Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review","volume":"8","author":"Stoner","year":"2015","journal-title":"Patient"},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0045","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/jps.20079","article-title":"Challenges in the development of high protein concentration formulations","volume":"93","author":"Shire","year":"2004","journal-title":"J. Pharm. Sci. USA"},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb0050","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.xphs.2018.01.007","article-title":"Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins","volume":"107","author":"Turner","year":"2018","journal-title":"J. Pharm. Sci. USA"},{"key":"10.1016\/j.addr.2026.115793_bb0055","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/DDDT.S287323","article-title":"Subcutaneous Delivery of High-Dose\/Volume Biologics: Current Status and Prospect for Future Advancements","volume":"15","author":"Badkar","year":"2021","journal-title":"Drug Des Dev Ther"},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb0060","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.xphs.2016.05.029","article-title":"Subcutaneous Injection Volume of Biopharmaceuticals-Pushing the Boundaries","volume":"105","author":"Mathaes","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115793_bb0065","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2020.02.036","article-title":"Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics","volume":"321","author":"Collins","year":"2020","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0070","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s11095-024-03683-5","article-title":"Clinical Investigation of Large Volume Subcutaneous Delivery up to 25 mL for Lean and Non-Lean Subjects","volume":"41","author":"Dang","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115793_bb0075","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","article-title":"Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge","volume":"167","author":"S\u00e1nchez-F\u00e9lix","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.addr.2026.115793_bb0080","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s40262-021-01023-z","article-title":"Estimation of Clearance and Bioavailability of Therapeutic Monoclonal Antibodies from Only Subcutaneous Injection Data in Humans Based on Comprehensive Analysis of Clinical Data","volume":"60","author":"Haraya","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb0085","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.xphs.2018.01.007","article-title":"Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins","volume":"107","author":"Turner","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115793_bb0090","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2020.02.036","article-title":"Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics","volume":"321","author":"Collins","year":"2020","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0095","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/17425247.2021.1853699","article-title":"Development of syringes and vials for delivery of biologics: current challenges and innovative solutions","volume":"18","author":"Yoneda","year":"2021","journal-title":"Expert Opin Drug Del"},{"issue":"9","key":"10.1016\/j.addr.2026.115793_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103914","article-title":"Development roadmap for subcutaneous delivery of high dose biologics - high concentration formulation, analytical comparability and patient preference considerations for large volume devices","volume":"114","author":"Ghosh","year":"2025","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb0105","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0110","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.xphs.2021.11.008","article-title":"Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis?","volume":"111","author":"Jiskoot","year":"2022","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0115","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2205540","article-title":"A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations","volume":"15","author":"Ghosh","year":"2023","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0120","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2211185","article-title":"High concentration formulation developability approaches and considerations","volume":"15","author":"Zarzar","year":"2023","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0125","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2285277","article-title":"Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume","volume":"15","author":"Desai","year":"2023","journal-title":"MAbs"},{"issue":"40","key":"10.1016\/j.addr.2026.115793_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202406604","article-title":"Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology","volume":"36","author":"Jacquot","year":"2024","journal-title":"Adv. Mater."},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0135","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1208\/s12248-025-01132-8","article-title":"Insights from a Survey of Drug Formulation Experts: Challenges and Preferences in High-Concentration Subcutaneous Biologic Drug Development","volume":"27","author":"Desai","year":"2025","journal-title":"AAPS J."},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103877","article-title":"Current and emerging strategies for subcutaneous delivery of high-concentration and high-dose antibody therapeutics","volume":"114","author":"Ren","year":"2025","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0145","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.xphs.2025.01.028","article-title":"Developing ultra-high concentration formulations of human immune globulins for subcutaneous injectables","volume":"114","author":"Yadav","year":"2025","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0150","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.xphs.2023.03.009","article-title":"Effect of Various Silicone Oil And Tungsten Levels on the Stability of a Monoclonal Antibody in Nine Commercially Available Prefilled Syringes","volume":"112","author":"Murphy","year":"2023","journal-title":"J. Pharm. Sci. USA"},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb0155","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1021\/acs.molpharmaceut.5c01837","article-title":"Molecular Mechanisms of Liraglutide Aggregation Induced by Dual Air-Water and Silicone-Oil-Water Interfacial Stress","volume":"23","author":"Hamada","year":"2026","journal-title":"Mol. Pharmaceutics"},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0160","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/jps.23973","article-title":"Protein aggregation and particle formation in prefilled glass syringes","volume":"103","author":"Gerhardt","year":"2014","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb0165","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/jps.24387","article-title":"Effect of the siliconization method on particle generation in a monoclonal antibody formulation in pre-filled syringes","volume":"104","author":"Gerhardt","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115793_bb0170","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jcis.2019.04.060","article-title":"Linking aggregation and interfacial properties in monoclonal antibody-surfactant formulations","volume":"550","author":"Kannan","year":"2019","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.addr.2026.115793_bb0175","series-title":"Characterizing Silicone Oil-Induced Protein Aggregation with Stimulated Raman Scattering Imaging","author":"Wong","year":"2023"},{"issue":"12","key":"10.1016\/j.addr.2026.115793_bb0180","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1002\/jps.22190","article-title":"Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies","volume":"99","author":"Yadav","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0185","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bpj.2012.04.047","article-title":"Weak Interactions Govern the Viscosity of Concentrated Antibody Solutions: High-Throughput Analysis Using the Diffusion Interaction Parameter","volume":"103","author":"Connolly","year":"2012","journal-title":"Biophys. J."},{"key":"10.1016\/j.addr.2026.115793_bb0190","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejpb.2017.06.029","article-title":"High-concentration protein formulations: How high is high?","volume":"119","author":"Garidel","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"13","key":"10.1016\/j.addr.2026.115793_bb0195","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.addr.2011.06.014","article-title":"Molecular level insight into intra-solvent interaction effects on protein stability and aggregation","volume":"63","author":"Shukla","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb0200","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1021\/nn204166z","article-title":"Concentrated Dispersions of Equilibrium Protein Nanoclusters That Reversibly Dissociate into Active Monomers","volume":"6","author":"Johnston","year":"2012","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0205","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejps.2013.04.019","article-title":"Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - Prediction of viscosity through protein-protein interaction measurements","volume":"49","author":"Neergaard","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb0210","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1021\/acs.jpcb.2c07616","article-title":"Characterizing Experimental Monoclonal Antibody Interactions and Clustering Using a Coarse-Grained Simulation Library and a Viscosity Model","volume":"127","author":"Chowdhury","year":"2023","journal-title":"J. Phys. Chem. B"},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb0215","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2174\/1389203719666171213114919","article-title":"Viscosity Control of Protein Solution by Small Solutes: A Review","volume":"19","author":"Hong","year":"2018","journal-title":"Curr Protein Pept Sc"},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0220","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/abt\/tbad022","article-title":"Effects of arginine in therapeutic protein formulations: a decade review and perspectives","volume":"6","author":"Ren","year":"2023","journal-title":"Antibody Ther."},{"issue":"22","key":"10.1016\/j.addr.2026.115793_bb0225","doi-asserted-by":"crossref","first-page":"7447","DOI":"10.1021\/jp111920y","article-title":"Arginine and the Hofmeister Series: The Role of Ion-Ion Interactions in Protein Aggregation Suppression","volume":"115","author":"Schneider","year":"2011","journal-title":"J. Phys. Chem. B"},{"issue":"9","key":"10.1016\/j.addr.2026.115793_bb0230","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1021\/acs.molpharmaceut.4c00460","article-title":"Flow Activation Energy of High-Concentration Monoclonal Antibody Solutions and Protein-Protein Interactions Influenced by NaCl and Sucrose","volume":"21","author":"Yuan","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115793_bb0240","unstructured":"1007\/s11095\u2013018\u20132398-1."},{"issue":"1\u20132","key":"10.1016\/j.addr.2026.115793_bb0245","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0377-8401(99)00071-1","article-title":"Comparison of the nutritive value for laying hens of diets containing atolls based on formulation using digestible protein and digestible amino acid versus total protein and total amino acid","volume":"81","author":"Khatun","year":"1999","journal-title":"Anim. Feed Sci. Technol."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0250","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/bit.22983","article-title":"Hydrophobic Salts Markedly Diminish Viscosity of Concentrated Protein Solutions","volume":"108","author":"Du","year":"2011","journal-title":"Biotechnol. Bioeng."},{"issue":"51","key":"10.1016\/j.addr.2026.115793_bb0255","doi-asserted-by":"crossref","first-page":"35947","DOI":"10.1039\/D3RA06476J","article-title":"Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry","volume":"13","author":"Rahban","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.addr.2026.115793_bb0260","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.copbio.2017.12.016","article-title":"Intermolecular interactions in highly concentrated formulations of recombinant therapeutic proteins","volume":"53","author":"Baek","year":"2018","journal-title":"Curr. Opin. Biotechnol."},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0275","first-page":"166","article-title":"Excipients and their use in injectable products","volume":"51","author":"Nema","year":"1997","journal-title":"PDA J. Pharm. Sci. Technol."},{"issue":"1\u20132","key":"10.1016\/j.addr.2026.115793_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.11.014","article-title":"Protein aggregation and its inhibition in biopharmaceutics","volume":"289","author":"Wang","year":"2005","journal-title":"Int. J. Pharm."},{"issue":"14","key":"10.1016\/j.addr.2026.115793_bb0285","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.1016\/S0021-9258(19)68947-7","article-title":"The Stabilization of Proteins by Sucrose","volume":"256","author":"Lee","year":"1981","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.addr.2026.115793_bb0290","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/js970143s","article-title":"Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2","volume":"86","author":"Lam","year":"1997","journal-title":"J. Pharm. Sci. USA"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0295","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.xphs.2019.10.015","article-title":"What Makes Polysorbate Functional? Impact of Polysorbate 80 Grade and Quality on IgG Stability During Mechanical Stress","volume":"109","author":"Grabarek","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0300","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.copbio.2009.10.006","article-title":"Formulation and manufacturability of biologics","volume":"20","author":"Shire","year":"2009","journal-title":"Curr. Opin. Biotechnol."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0305","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/bp070462h","article-title":"Current perspectives on stability of protein drug products during formulation, fill and finish operations","volume":"24","author":"Rathore","year":"2008","journal-title":"Biotechnol. Prog."},{"issue":"7","key":"10.1016\/j.addr.2026.115793_bb0310","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/bit.23155","article-title":"Aggregates in Monoclonal Antibody Manufacturing Processes","volume":"108","author":"V\u00e1zquez-Rey","year":"2011","journal-title":"Biotechnol. Bioeng."},{"issue":"11","key":"10.1016\/j.addr.2026.115793_bb0315","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1002\/bit.27510","article-title":"Strategies for high-concentration drug substance manufacturing to facilitate subcutaneous administration: A review","volume":"117","author":"Holstein","year":"2020","journal-title":"Biotechnol. Bioeng."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0320","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.xphs.2018.10.031","article-title":"Syringe Filling of a High-Concentration mAb Formulation: Experimental, Theoretical, and Computational Evaluation of Filling Process Parameters That Influence the Propensity for Filling Needle Clogging","volume":"108","author":"Hanslip","year":"2019","journal-title":"J. Pharm. Sci. USA"},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb0325","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1002\/jps.22545","article-title":"A New Roadmap for Biopharmaceutical Drug Product Development: Integrating Development, Validation, and Quality by Design","volume":"100","author":"Martin-Moe","year":"2011","journal-title":"J. Pharm. Sci. USA"},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0330","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.xphs.2020.12.016","article-title":"Product-Specific Impact of Viscosity Modulating Formulation Excipients During Ultra-High Concentration Biotherapeutics Drug Product Development","volume":"110","author":"Rodrigues","year":"2021","journal-title":"J. Pharm. Sci. USA"},{"issue":"11","key":"10.1016\/j.addr.2026.115793_bb0335","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1016\/j.xphs.2017.06.017","article-title":"A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities","volume":"106","author":"Whitaker","year":"2017","journal-title":"J. Pharm. Sci. USA"},{"issue":"1\u20132","key":"10.1016\/j.addr.2026.115793_bb0340","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijpharm.2018.08.043","article-title":"Protein aggregation - Mechanisms, detection, and control","volume":"550","author":"Wang","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115793_bb0345","first-page":"1313","volume":"40","author":"Chen","year":"2023","journal-title":"Enabling efficient design of biological formulations through advanced characterizations"},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0350","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/abt\/tbab027","article-title":"US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives","volume":"4","author":"Wang","year":"2021","journal-title":"Antibody Therapeutics"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0355","first-page":"11","article-title":"Root cause analysis of tungsten-induced protein aggregation in pre-filled syringes","volume":"64","author":"Liu","year":"2010","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115793_bb0360","first-page":"1","article-title":"Effect of Various Silicone Oil and Tungsten Levels on the Stability of a Monoclonal Antibody in Nine Commercially Available Prefilled Syringes","volume":"000","author":"Murphy","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0365","doi-asserted-by":"crossref","first-page":"674","DOI":"10.5731\/pdajpst.2020.011627","article-title":"Drug formulation impact on prefilled syringe functionality and autoinjector performance","volume":"74","author":"Fang","year":"2020","journal-title":"PDA J. Pharm. Sci. Technol."},{"issue":"12","key":"10.1016\/j.addr.2026.115793_bb0370","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1002\/jps.24654","article-title":"Surfactant effects on particle generation in antibody formulations in pre-filled syringes","volume":"104","author":"Gerhardt","year":"2015","journal-title":"J. Pharm. Sci. USA"},{"issue":"11","key":"10.1016\/j.addr.2026.115793_bb0375","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1016\/j.xphs.2020.07.033","article-title":"Impact of surfactants on the functionality of prefilled syringes","volume":"109","author":"Wang","year":"2020","journal-title":"J. Pharm. Sci. USA"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0380","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5731\/pdajpst.2017.008169","article-title":"Impact of drug formulation variables on silicone oil structure and functionality of prefilled syringe system","volume":"72","author":"Shi","year":"2018","journal-title":"PDA J. Pharm. Sci. Technol."},{"issue":"12","key":"10.1016\/j.addr.2026.115793_bb0385","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.xphs.2022.09.015","article-title":"The Impact of Syringe Age Prior to Filling on Migration of Subvisible Silicone-Oil Particles into Drug Product","volume":"111","author":"Song","year":"2022","journal-title":"J. Pharm. Sci. USA"},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0390","first-page":"66","article-title":"Assessing Flange Strength and Dimensional Variability","volume":"12","author":"Murray","year":"2014","journal-title":"BioProcess International"},{"key":"10.1016\/j.addr.2026.115793_bb0395","series-title":"STANDARD Glass barrels for injectables and sterilized subassembled syringes ready for filling","author":"INTERNATIONAL","year":"2015"},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0400","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4103\/2230-973X.93004","article-title":"Prefilled syringes: An innovation in parenteral packaging","volume":"1","author":"Basu","year":"2011","journal-title":"Int. J. Pharm. Investig."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0405","first-page":"88","article-title":"Packaging Why do Pharmaceutical Glass Containers Break : The Underestimated Power of Strength Testing and Fractography","volume":"8","author":"Haines","year":"2016","journal-title":"Int. Pharm. Ind."},{"issue":"12","key":"10.1016\/j.addr.2026.115793_bb0415","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s11095-024-03795-y","article-title":"Glass Silicone Oil Free Pre-filled Syringe as Primary Container in Autoinjector","volume":"41","author":"Zhao","year":"2024","journal-title":"Pharm Res-Dordr"},{"key":"10.1016\/j.addr.2026.115793_bb0420","first-page":"255","article-title":"Usability of a new disposable autoinjector platform device: Results of a formative study conducted with a broad user population","volume":"8","author":"Lange","year":"2015","journal-title":"Medical Devices: Evidence and Research"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0425","doi-asserted-by":"crossref","DOI":"10.1186\/s41120-018-0027-z","article-title":"Improving the safety of disposable auto-injection devices: a systematic review of use errors","volume":"4","author":"Weinhold","year":"2018","journal-title":"AAPS Open"},{"issue":"00","key":"10.1016\/j.addr.2026.115793_bb0430","first-page":"1","article-title":"Expert Opinion on Drug Delivery Formative and Validation Human Factors studies of a new disposable autoinjector for subcutaneous delivery of chronic disease therapies Formative and Validation Human Factors studies of a new disposable autoinjector for subc","volume":"00","author":"Lageat","year":"2021","journal-title":"Expert Opin Drug Del"},{"key":"10.1016\/j.addr.2026.115793_bb0435","series-title":"Nesbitt. Development of Biopharmaceutical Drug-Device Products","author":"Feroz Jameel","year":"2020"},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0440","first-page":"274","article-title":"Coring and Fragmentation of Elastomeric Needle Shield in a Pre-Filled Syringe","volume":"79","author":"Babaee","year":"2025","journal-title":"PDA J. Pharm. Sci. Technol."},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb0445","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jclinane.2013.10.007","article-title":"The incidence of coring with blunt versus sharp needles","volume":"26","author":"Wani","year":"2014","journal-title":"J. Clin. Anesth."},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb0450","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jclinane.2015.01.009","article-title":"The incidence of coring and fragmentation of medication vial rubber stoppers","volume":"27","author":"Eskander","year":"2015","journal-title":"J. Clin. Anesth."},{"key":"10.1016\/j.addr.2026.115793_bb0455","series-title":"Expert Opinion on Drug Delivery Biopharmaceutical formulations for pre-filled delivery devices Biopharmaceutical formulations for pre-filled delivery devices","volume":"5247","author":"Jezek","year":"2013"},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0460","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/jps.21530","article-title":"Overlooking Subvisible Particles in Therapeutic Protein Products\u202f: Gaps That May Compromise Product Quality","volume":"98","author":"Carpenter","year":"2009","journal-title":"J. Pharm. Sci. USA"},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0465","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/jps.20321","article-title":"Silicone Oil Induced Aggregation of Proteins","volume":"94","author":"Jones","year":"2005","journal-title":"J. Pharm. Sci. USA"},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb0470","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jps.24184","article-title":"Effects of Syringe Material and Silicone Oil Lubrication on the","volume":"104","author":"Krayukhina","year":"2015","journal-title":"J. Pharm. Sci. USA"},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0475","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5731\/pdajpst.2017.007997","article-title":"Methods to determine the silicone oil layer thickness in sprayed-on siliconized syringes","volume":"72","author":"Loosli","year":"2018","journal-title":"PDA J. Pharm. Sci. Technol."},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb0480","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1080\/03007995.2020.1783219","article-title":"Performance characterization of spring actuated autoinjector devices for Emgality and Aimovig","volume":"36","author":"Dou","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"issue":"9","key":"10.1016\/j.addr.2026.115793_bb0485","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1021\/acs.molpharmaceut.2c00152","article-title":"Differential Surface Adsorption Phenomena for Conventional and Novel Surfactants Correlates with Changes in Interfacial mAb Stabilization","volume":"19","author":"Kanthe","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115793_bb0490","series-title":"Variables Impacting Silicone Oil Migration and Biologics in Pre filled Syringes","volume":"112","author":"Hamzaoui","year":"2023"},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb0500","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.xphs.2023.05.017","article-title":"Variables Impacting Silicone Oil Migration and Biologics in Prefilled Syringes","volume":"112","author":"Gentile","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb0505","article-title":"Cross-Linked Silicone Coating: A Novel Prefilled Syringe Technology That Reduces Subvisible Particles and Maintains Compatibility with Biologics","volume":"103","author":"Depaz","year":"2014","journal-title":"J. Pharm. Sci. USA"},{"key":"10.1016\/j.addr.2026.115793_bb0510","first-page":"194","article-title":"Safety of silicone oils as intraocular medical device: An in vitro cytotoxicity study","author":"Romano","year":"2020","journal-title":"Exp. Eye Res."},{"issue":"11","key":"10.1016\/j.addr.2026.115793_bb0515","article-title":"Can Cross-Linked Siliconized PFS Come to the Rescue of the Biologics Drug Product?","volume":"109","author":"Thakare","year":"2020","journal-title":"J. Pharm. Sci. USA"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0520","doi-asserted-by":"crossref","DOI":"10.3109\/10837450.2014.982825","article-title":"Pre-filled syringes: a review of the history, manufacturing and challenges","volume":"20","author":"Sacha","year":"2015","journal-title":"Pharm. Dev. Technol."},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0525","doi-asserted-by":"crossref","DOI":"10.1080\/17425247.2021.1853699","article-title":"Development of syringes and vials for delivery of biologics: current challenges and innovative solutions","volume":"18","author":"Yoneda","year":"2021","journal-title":"Expert Opin Drug Del"},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb0530","first-page":"149","article-title":"Distribution of silicone oil in prefilled glass syringes probed with optical and spectroscopic methods","volume":"63","author":"Wen","year":"2009","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115793_bb0535","first-page":"105","article-title":"Optimization of the bake-on siliconization of cartridges. Part II: Investigations into burn-in time and temperature","author":"Funke","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"12","key":"10.1016\/j.addr.2026.115793_bb0540","article-title":"Silicone Migration From Baked-on Silicone Layers Particle Characterization in Placebo and Protein Solutions","volume":"105","author":"Funke","year":"2016","journal-title":"J. Pharm. Sci. USA"},{"key":"10.1016\/j.addr.2026.115793_bb0545","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-90603-4_9","article-title":"Development of Prefilled Syringe Combination Products for Biologics","author":"Dimitrova","year":"2018","journal-title":"Challenges Protein Product Develop."},{"key":"10.1016\/j.addr.2026.115793_bb0550","first-page":"80","article-title":"Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections","author":"Melo","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0555","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.xphs.2025.01.025","article-title":"Centrifuge siliconization of primary container systems","volume":"114","author":"Wong","year":"2025","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0560","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/jps.23973","article-title":"Protein Aggregation and Particle Formation in Prefilled Glass Syringes","volume":"103","author":"Gerhardt","year":"2014","journal-title":"J. Pharm. Sci. USA"},{"key":"10.1016\/j.addr.2026.115793_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2022.01.028","article-title":"Risk Mitigation of Plunger-Stopper Displacement Under Low Atmospheric Pressure by Establishing Design Space for Filling-Stoppering Process of Prefilled Syringes: A Design of Experiment (DoE) Approach","author":"Mehta","year":"2022","journal-title":"J. Pharm. Sci. USA"},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0570","article-title":"Gelation of a monoclonal antibody at the silicone oil\u2013water interface and subsequent rupture of the interfacial gel results in aggregation and particle formation","volume":"104","author":"Mehta","year":"2015","journal-title":"J. Pharm. Sci. USA"},{"key":"10.1016\/j.addr.2026.115793_bb0575","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-022-03334-7","article-title":"Assessment of cavitation intensity in spring-driven autoinjectors","author":"Eshraghi","year":"2022","journal-title":"Pharm Res-Dordr"},{"key":"10.1016\/j.addr.2026.115793_bb0580","doi-asserted-by":"crossref","first-page":"120008","DOI":"10.1016\/j.ijpharm.2020.120008","article-title":"An experimentally validated dynamic model for spring-driven autoinjectors","volume":"594","author":"Zhong","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"April","key":"10.1016\/j.addr.2026.115793_bb0585","doi-asserted-by":"crossref","first-page":"122975","DOI":"10.1016\/j.ijpharm.2023.122975","article-title":"Hydrodynamic considerations for spring-driven autoinjector design","volume":"640","author":"Zhong","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0590","doi-asserted-by":"crossref","first-page":"674","DOI":"10.5731\/pdajpst.2020.011627","article-title":"Drug Formulation Impact on Prefilled Syringe Functionality and Autoinjector Performance","volume":"74","author":"Fang","year":"2020","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115793_bb0595","series-title":"Development of an advanced injection time model for an autoinjector","first-page":"215","author":"Thueer","year":"2018"},{"key":"10.1016\/j.addr.2026.115793_bb0600","first-page":"1","article-title":"Clinical Evaluation of an Investigational 5 mL Wearable Injector in Healthy Human Subjects","author":"Woodley","year":"2021","journal-title":"Clin. Transl. Sci."},{"issue":"617","key":"10.1016\/j.addr.2026.115793_bb0605","first-page":"121588","article-title":"A framework to optimize spring-driven autoinjectors","volume":"2022","author":"Zhong","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.addr.2026.115793_bb0610","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4155\/tde.12.68","article-title":"High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective","volume":"3","author":"Narasimhan","year":"2012","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2026.115793_bb0615","series-title":"Form-Tocilizumab","author":"Therapeutic Biological Establishment Evaluation Request (TB-EER)","year":"2013"},{"issue":"127","key":"10.1016\/j.addr.2026.115793_bb0620","first-page":"104","article-title":"Clogging in staked-in needle pre-filled syringes (SIN-PFS): Influence of water vapor transmission through the needle shield","volume":"2018","author":"De Bardi","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"May","key":"10.1016\/j.addr.2026.115793_bb0625","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejpb.2018.05.006","article-title":"On the needle clogging of staked-in-needle pre-filled syringes: Mechanism of liquid entering the needle and solidification process","volume":"128","author":"De Bardi","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0630","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11095-024-03673-7","article-title":"Unraveling Pre-filled Syringe Needle Clogging: Exploring a Fresh Outlook Through Innovative Techniques","volume":"41","author":"Hu","year":"2024","journal-title":"Pharm. Res."},{"issue":"August","key":"10.1016\/j.addr.2026.115793_bb0635","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejpb.2022.08.008","article-title":"European Journal of Pharmaceutics and Biopharmaceutics Viscosity increase \/ gelation of therapeutic IgG monoclonal antibodies induced by Zn 2 +\u202f: One possible root cause of clogging of staked-in-needle prefilled syringes","volume":"178","author":"Fukuda","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb0640","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s11095-025-03888-2","article-title":"Investigating Zinc Migration from Rigid Needle Shield to Drug Formulation in Needle Tip of Pre-filled Syringe","volume":"42","author":"Hu","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115793_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114615","article-title":"Does needle clogging change the spatial distribution of injected drug in tissue? New insights by X-ray computed tomography","volume":"207","author":"Bonaventura","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bib1497","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1021\/acs.molpharmaceut.5c01652","article-title":"Mechanistic Investigation of Zn(II) Extraction and Interactions in Combination Biological Drug Products","volume":"23","author":"Song","year":"2026","journal-title":"Mol. Pharmaceutics"},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb0650","first-page":"42","article-title":"A rational approach to determining the maximum allowable gas bubble inside a pre-filled syringe to minimize stopper movement and protect product sterility","volume":"9","author":"Kinney","year":"2009","journal-title":"Drug Delivery Technol."},{"key":"10.1016\/j.addr.2026.115793_bb0655","series-title":"Evaluation of Plunger Movement During Transit Conditions of West\u2019s 1 mL Long and 1\u20133 mL NovaPure\u00ae 4023\/50 Gray FluroTec\u00ae Plungers","author":"West Technical","year":"2016"},{"key":"10.1016\/j.addr.2026.115793_bb0660","series-title":"NovaPure\u00ae 1\u20133 mL 4023 \/ 50 Gray Plunger vs. Article 2345 4023 \/ 50 Gray Plunger Performance Comparison in Syringe Barrels (Vendor 1)","author":"West Technical","year":"2019"},{"key":"10.1016\/j.addr.2026.115793_bb0665","series-title":"Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions Draft Guidance for Industry and Food and Drug","author":"Fda","year":"2021"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.104024","article-title":"A Monte Carlo simulation-based approach to define target fill volume and stopper insertion depth for manufacturing pre-filled syringe combination products","volume":"115","author":"Kuo","year":"2026","journal-title":"J. Pharm. Sci."},{"issue":"0123456789","key":"10.1016\/j.addr.2026.115793_bb0675","article-title":"A Novel Method to Optimize Drug Delivery for Parenteral Products Involving New Therapies and Unmet Needs","volume":"3","author":"Khanolkar","year":"2023","journal-title":"Pharm Res-Dordr"},{"key":"10.1016\/j.addr.2026.115793_bb0680","series-title":"ISO 11040-8 INTERNATIONAL STANDARD: Requirements and test methods for finished prefilled syringes","author":"Iso","year":"2021"},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb0685","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1208\/s12249-015-0288-y","article-title":"Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects","volume":"16","author":"Dias","year":"2015","journal-title":"AAPS PharmSciTech"},{"issue":"00","key":"10.1016\/j.addr.2026.115793_bb0690","first-page":"1","article-title":"Expert opinion on drug delivery enabling faster subcutaneous delivery of larger volume, high viscosity fluids abstract","volume":"00","author":"Rini","year":"2022","journal-title":"Expert Opin Drug Del"},{"key":"10.1016\/j.addr.2026.115793_bb0695","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s13346-023-01318-7","article-title":"Imaging of large volume subcutaneous deposition using MRI: exploratory clinical study results","author":"Pettis","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.addr.2026.115793_bb0700","series-title":"Characterization of large volume subcutaneous injections using computed tomography imaging and simultaneous pressure measurements","first-page":"1","volume":"2008(July)","author":"Purcell","year":"2023"},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0705","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5731\/pdajpst.2018.009357","article-title":"Local concentrating, not shear stress, that may lead to possible instability of protein molecules during syringe injection: a fluid dynamic study with two-phase flow model","volume":"73","author":"Xing","year":"2019","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115793_bb0710","article-title":"Alternative Cannula Configurations to Control Fluid Distribution in Tissue","author":"Scott Brown","year":"2021","journal-title":"US20230114337A1"},{"issue":"7","key":"10.1016\/j.addr.2026.115793_bb0715","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1016\/j.xphs.2021.03.017","article-title":"A review of Formulations of Commercially Available Antibodies","volume":"110","author":"Strickley","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115793_bb0720","series-title":"Subcutaneous Injection Performance in Yucatan Miniature Pigs with and without Human Hyaluronidase and Auto-injector Tolerability in Humans","first-page":"1","author":"Shi","year":"2021"},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0725","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/bjc.2013.371","article-title":"Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase","volume":"109","author":"Shpilberg","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0730","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1208\/s12248-023-00811-8","article-title":"Long-acting injectable aqueous suspensions\u2014summary from an AAPS Workshop","volume":"25","author":"Holm","year":"2023","journal-title":"AAPS J."},{"issue":"7","key":"10.1016\/j.addr.2026.115793_bb0735","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s11095-023-03470-8","article-title":"A retrospective analysis of preclinical and clinical pharmacokinetics from administration of long-acting aqueous suspensions","volume":"40","author":"Johnson","year":"2023","journal-title":"Pharm Res-Dordr"},{"key":"10.1016\/j.addr.2026.115793_bb0740","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jconrel.2021.12.011","article-title":"Effect of particle size on in vivo performances of long-acting injectable drug suspension","volume":"341","author":"Ho","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115793_bb0745","first-page":"5","article-title":"Pembrolizumab microgravity crystallization experimentation","author":"Reichert","year":"2019","journal-title":"Npj Microgravity"},{"issue":"12","key":"10.1016\/j.addr.2026.115793_bb0755","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1021\/acs.molpharmaceut.4c00929","article-title":"Investigation of Protein Therapeutics in Frozen Conditions Using DNP MAS NMR: A Study on Pembrolizumab","volume":"21","author":"Banks","year":"2024","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb0760","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1021\/acs.molpharmaceut.4c00418","article-title":"Small-Angle X-ray Scattering as a Powerful Tool for Phase and Crystallinity Assessment of Monoclonal Antibody Crystallites in Support of Batch Crystallization","volume":"21","author":"Larpent","year":"2024","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0765","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1021\/acs.molpharmaceut.1c00915","article-title":"Investigating Crystalline Protein Suspension Formulations of Pembrolizumab from MAS NMR Spectroscopy","volume":"19","author":"Li","year":"2022","journal-title":"Mol. Pharm."},{"issue":"19","key":"10.1016\/j.addr.2026.115793_bb0770","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1039\/c0sm00110d","article-title":"Jamming and unjamming of concentrated colloidal dispersions in channel flows","volume":"6","author":"Campbell","year":"2010","journal-title":"Soft Matter"},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb0775","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1039\/c0sm01338b","article-title":"Crystallization and intermittent dynamics in constricted microfluidic flows of dense suspensions","volume":"7","author":"Genovese","year":"2011","journal-title":"Soft Matter"},{"issue":"41","key":"10.1016\/j.addr.2026.115793_bb0780","doi-asserted-by":"crossref","first-page":"7657","DOI":"10.1039\/C7SM00806F","article-title":"Friction controls even submerged granular flows","volume":"13","author":"Koivisto","year":"2017","journal-title":"Soft Matter"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0785","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1039\/C6SM01879C","article-title":"Clogging of microfluidic systems","volume":"13","author":"Dressaire","year":"2017","journal-title":"Soft Matter"},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0790","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevE.96.062605","article-title":"Clogging of soft particles in two-dimensional hoppers","volume":"96","author":"Hong","year":"2017","journal-title":"Phys. Rev. E"},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb0795","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevE.97.021102","article-title":"Clogging in constricted suspension flows","volume":"97","author":"Marin","year":"2018","journal-title":"Phys. Rev. E"},{"key":"10.1016\/j.addr.2026.115793_bb0800","series-title":"Vibrating Injection of Dense Suspensions","author":"Khater","year":"2023"},{"issue":"12","key":"10.1016\/j.addr.2026.115793_bb0805","doi-asserted-by":"crossref","DOI":"10.1063\/5.0178933","article-title":"Characterizing jamming of dilute and semi-dilute fiber suspensions in a sudden contraction and a T-junction","volume":"35","author":"Villalba","year":"2023","journal-title":"Phys. Fluids"},{"key":"10.1016\/j.addr.2026.115793_bb0810","article-title":"Preparation of injectable suspensions having improved injectability","author":"Ramstack","year":"2010","journal-title":"Google Patents US6495164B1"},{"key":"10.1016\/j.addr.2026.115793_bb0815","doi-asserted-by":"crossref","first-page":"A40","DOI":"10.1017\/jfm.2022.981","article-title":"Role of liquid driving on the clogging of constricted particle suspensions","volume":"953","author":"Souzy","year":"2022","journal-title":"J. Fluid Mech."},{"issue":"31","key":"10.1016\/j.addr.2026.115793_bb0820","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1039\/D1SM00738F","article-title":"Roughness-dependent clogging of particle suspensions flowing into a constriction","volume":"17","author":"Hsu","year":"2021","journal-title":"Soft Matter"},{"issue":"36","key":"10.1016\/j.addr.2026.115793_bb0825","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1039\/D2SM00962E","article-title":"Influence of the solid fraction on the clogging by bridging of suspensions in constricted channels","volume":"18","author":"Vani","year":"2022","journal-title":"Soft Matter"},{"issue":"12","key":"10.1016\/j.addr.2026.115793_bb0830","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1016\/j.xphs.2024.09.026","article-title":"Injectability of high concentrated suspensions using model microparticles","volume":"113","author":"Kowsari","year":"2024","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0835","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.xphs.2023.12.022","article-title":"A review of recent FDA-approved biologic-device combination products","volume":"113","author":"Guo","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115793_bb0840","series-title":"Colloidal dynamics in flow and confinement","author":"Ghosh","year":"2015"},{"issue":"18","key":"10.1016\/j.addr.2026.115793_bb0845","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevLett.92.185506","article-title":"Jamming, two-fluid behavior, and \u201cself-filtration\u201d in concentrated particulate suspensions","volume":"92","author":"Haw","year":"2004","journal-title":"Phys. Rev. Lett."},{"issue":"7","key":"10.1016\/j.addr.2026.115793_bb0850","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1208\/s12249-025-03167-8","article-title":"Alternative Syringe and Needle Design for Clog-free Delivery of High-concentration Suspensions","volume":"26","author":"Kowsari","year":"2025","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0855","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/(SICI)1520-6017(200003)89:3<297::AID-JPS2>3.0.CO;2-P","article-title":"Lymphatic transport of proteins after subcutaneous administration","volume":"89","author":"Porter","year":"2000","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0860","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic determinants of biotherapeutics absorption following SC administration","volume":"14","author":"Richter","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115793_bb0865","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1749-6632.2002.tb04880.x","article-title":"The role of interstitial stress in lymphatic function and lymphangiogenesis","volume":"979","author":"Swartz","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb0870","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1015880819328","article-title":"Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration","volume":"7","author":"Supersaxo","year":"1990","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0875","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2005.05.006","article-title":"Subcutaneous drug delivery and the role of the lymphatics","volume":"2","author":"McLennan","year":"2005","journal-title":"Drug Discov. Today Technol."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0880","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0022-3565(24)39226-2","article-title":"Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs","volume":"293","author":"Chen","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.addr.2026.115793_bb0885","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1124\/dmd.113.051524","article-title":"Lymphatic absorption, metabolism, and excretion of a therapeutic peptide in dogs and rats","volume":"41","author":"Zou","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb0890","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11095-011-0578-3","article-title":"Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats","volume":"29","author":"Kagan","year":"2012","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.addr.2026.115793_bb0895","first-page":"700","article-title":"Lymphatic transport of recombinant human tumor necrosis factor in rats","volume":"11","author":"Kojima","year":"1988","journal-title":"Aust. J. Pharm."},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb0900","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/jps.23058","article-title":"Noninvasive real-time fluorescence imaging of the lymphatic uptake of BSA-IRDye 680 conjugate administered subcutaneously in mice","volume":"101","author":"Wu","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115793_bb0905","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2015.07.016","article-title":"A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components","volume":"214","author":"Kinnunen","year":"2015","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0910","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4155\/tde.11.31","article-title":"Electrostatic interactions of monoclonal antibodies with subcutaneous tissue","volume":"2","author":"Mach","year":"2011","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2026.115793_bb0915","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jconrel.2018.01.015","article-title":"In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies","volume":"273","author":"Bown","year":"2018","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb0920","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0925","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb0930","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1124\/dmd.111.043604","article-title":"Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs","volume":"40","author":"Wang","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb0935","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/(SICI)1520-6017(200002)89:2<168::AID-JPS4>3.0.CO;2-Q","article-title":"Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection","volume":"89","author":"Charman","year":"2000","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb0940","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10928-020-09691-3","article-title":"Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling","volume":"47","author":"Hu","year":"2020","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"1s","key":"10.1016\/j.addr.2026.115793_bb0945","doi-asserted-by":"crossref","first-page":"130s","DOI":"10.18433\/jpps30028","article-title":"Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model","volume":"21","author":"Varkhede","year":"2018","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0950","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jcph.4","article-title":"The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model","volume":"53","author":"Zhao","year":"2013","journal-title":"J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.addr.2026.115793_bb0955","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/acs.molpharmaceut.4c00132","article-title":"Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution","volume":"21","author":"Milewski","year":"2024","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0960","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.dmpk.2017.05.002","article-title":"Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human","volume":"32","author":"Haraya","year":"2017","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb0965","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4161\/mabs.4.2.19387","article-title":"Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration","volume":"4","author":"Zheng","year":"2012","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb0970","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/protein\/gzq009","article-title":"Reduced elimination of IgG antibodies by engineering the variable region","volume":"23","author":"Igawa","year":"2010","journal-title":"Protein Eng. Des. Sel."},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb0975","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1208\/s12248-023-00818-1","article-title":"Predicting Human Bioavailability of Subcutaneously Administered Monoclonal Antibodies Using Non-human Primate Linear Clearance and Antibody Isoelectric Point","volume":"25","author":"Zou","year":"2023","journal-title":"AAPS J."},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb0980","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/bdd.1925","article-title":"Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration","volume":"36","author":"Fathallah","year":"2015","journal-title":"Biopharm. Drug Dispos."},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0985","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1007\/s12325-022-02126-0","article-title":"Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials","volume":"39","author":"Chabra","year":"2022","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb0990","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cpdd.617","article-title":"Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers","volume":"8","author":"Kotani","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0995","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/cpdd.805","article-title":"Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects","volume":"10","author":"Li","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb1000","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/cpdd.54","article-title":"Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects","volume":"2","author":"Cai","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb1005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bcp.14155","article-title":"Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients","volume":"86","author":"Bruin","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb1010","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/0091270009340782","article-title":"Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects","volume":"50","author":"Xu","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb1015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/02770903.2019.1663428","article-title":"Comparison of autoinjector with accessorized prefilled syringe for benralizumab pharmacokinetic exposure: AMES trial results","volume":"58","author":"Martin","year":"2021","journal-title":"J. Asthma"},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb1020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1208\/s12248-020-0433-8","article-title":"Systematic Review of Device Parameters and Design of Studies Bridging Biologic-Device Combination Products Using Prefilled Syringes and Autoinjectors","volume":"22","author":"Hu","year":"2020","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb1025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/cpdd.60","article-title":"Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites","volume":"3","author":"Ortega","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"10.1016\/j.addr.2026.115793_bb1030","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.xphs.2017.05.030","article-title":"Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins","volume":"106","author":"Hamuro","year":"2017","journal-title":"J. Pharm. Sci. USA"},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb1035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40259-020-00465-4","article-title":"Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins","volume":"35","author":"Jarvi","year":"2021","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb1040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin. Pharmacol. Ther. (St. Louis, MO, U. S.)"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb1045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4161\/hv.4.1.4747","article-title":"Evidence based route of administration of vaccines","volume":"4","author":"Cook","year":"2008","journal-title":"Hum. Vaccin."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb1050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/ilar.46.3.241","article-title":"Applications and optimization of immunization procedures","volume":"46","author":"Schunk","year":"2005","journal-title":"ILAR J."},{"issue":"12","key":"10.1016\/j.addr.2026.115793_bb1055","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1002\/eji.201343790","article-title":"Human dendritic cells - stars in the skin","volume":"43","author":"Klechevsky","year":"2013","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb1060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nri3683","article-title":"The origins and functions of dendritic cells and macrophages in the skin","volume":"14","author":"Malissen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb1065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/1547691X.2013.821564","article-title":"Immunogenicity of therapeutic proteins: influence of aggregation","volume":"11","author":"Ratanji","year":"2014","journal-title":"J. Immunotoxicol."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb1070","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb1075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02678213","article-title":"Treatment-induced antibodies to interleukin-2","volume":"10","author":"Prummer","year":"1997","journal-title":"Biotherapy"},{"issue":"10","key":"10.1016\/j.addr.2026.115793_bb1080","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1002\/jps.21672","article-title":"Evaluation of the Immuno-Stimulatory Potential of Stopper Extractables and Leachables by Using Dendritic Cells as Readout","volume":"98","author":"Mueller","year":"2009","journal-title":"J. Pharm. Sci. USA"},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb1085","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1007\/s11095-011-0385-x","article-title":"The Degradation of Polysorbates 20 and 80 and its Potential Impact on the Stability of Biotherapeutics","volume":"28","author":"Kishore","year":"2011","journal-title":"Pharm Res-Dordr"},{"issue":"12","key":"10.1016\/j.addr.2026.115793_bb1090","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1073\/pnas.1131899100","article-title":"Crystalline monoclonal antibodies for subcutaneous delivery","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115793_bb1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115480","article-title":"Biopharmaceutical drug delivery and phototherapy using protein crystals","volume":"216","author":"Zhou","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb1100","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1208\/s12248-013-9510-6","article-title":"Immunogenicity of Subcutaneously Administered Therapeutic Proteins-a Mechanistic Perspective","volume":"15","author":"Fathallah","year":"2013","journal-title":"AAPS J."},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb1105","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/jps.24513","article-title":"Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice","volume":"104","author":"Ramakrishnan","year":"2015","journal-title":"J. Pharm. Sci. USA"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb1110","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2577159","article-title":"Integrating computational simulation and high-throughput screening for the development of robust ultra-high concentration formulation of IgG1 antibody","volume":"17","author":"Lyu","year":"2025","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb1115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1021\/acssynbio.2c00426","article-title":"Functional Deimmunization of Botulinum Neurotoxin Protease Domain via Computationally Driven Library Design and Ultrahigh-Throughput Screening","volume":"12","author":"Fang","year":"2023","journal-title":"ACS Synth. Biol."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb1120","article-title":"A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics","volume":"3","author":"Jarvi","year":"2023","journal-title":"Commun Med-London"},{"issue":"7","key":"10.1016\/j.addr.2026.115793_bb1130","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.tibtech.2014.05.005","article-title":"Therapeutic protein aggregation: mechanisms, design, and control","volume":"32","author":"Roberts","year":"2014","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.addr.2026.115793_bb1135","article-title":"Molecular mechanisms for stabilizing biologics in the solid state","author":"Ling","year":"2024","journal-title":"J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.addr.2026.115793_bb1265","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1016\/j.xphs.2021.07.007","article-title":"Influence of Protein Adsorption on Aggregation in Prefilled Syringes","volume":"110","author":"Yoneda","year":"2021","journal-title":"J. Pharm. Sci. USA"},{"key":"10.1016\/j.addr.2026.115793_bb1270","series-title":"Biophysical Characterization of Proteins in Developing Biopharmaceuticals","author":"Houde","year":"2020"},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb1275","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.xphs.2021.11.024","article-title":"Oxidation and Deamidation of Monoclonal Antibody Products: Potential Impact on Stability, Biological Activity, and Efficacy","volume":"111","author":"Gupta","year":"2022","journal-title":"J. Pharm. Sci. USA"},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb1280","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/19420862.2017.1368602","article-title":"Forced degradation of recombinant monoclonal antibodies: A practical guide","volume":"9","author":"Nowak","year":"2017","journal-title":"Mabs"},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb1140","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.xphs.2017.10.013","article-title":"Effect of Phosphate Ion on the Structure of Lumazine Synthase, an Antigen Presentation System From Bacillus anthracis","volume":"107","author":"Wei","year":"2018","journal-title":"J. Pharm. Sci. USA"},{"issue":"29","key":"10.1016\/j.addr.2026.115793_bb1145","doi-asserted-by":"crossref","first-page":"11937","DOI":"10.1073\/pnas.0904191106","article-title":"Design of therapeutic proteins with enhanced stability","volume":"106","author":"Chennamsetty","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb1150","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1021\/jp3091717","article-title":"Cosolute Effects on the Chemical Potential and Interactions of an IgG1 Monoclonal Antibody at High Concentrations","volume":"117","author":"Scherer","year":"2013","journal-title":"J. Phys. Chem. B"},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb1155","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12551-016-0218-6","article-title":"Dynamic light scattering: a practical guide and applications in biomedical sciences","volume":"8","author":"Stetefeld","year":"2016","journal-title":"Biophys. Rev."},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb1160","first-page":"41","article-title":"Stability Testing of Protein Therapeutics Using DLS","volume":"34","author":"Mirasol","year":"2021","journal-title":"BioPharm International, BioPharm International"},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb1165","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/jps.24237","article-title":"Mechanism of Reversible Self-Association of a Monoclonal Antibody: Role of Electrostatic and Hydrophobic Interactions","volume":"104","author":"Esfandiary","year":"2015","journal-title":"J. Pharm. Sci. USA"},{"issue":"7","key":"10.1016\/j.addr.2026.115793_bb1170","first-page":"46","article-title":"Enhanced Protein Structural Characterization Using Microfluidic Modulation Spectroscopy","volume":"33","author":"Wang","year":"2018","journal-title":"Spectroscopy"},{"key":"10.1016\/j.addr.2026.115793_bb1175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2022.114629","article-title":"Advancing secondary structure characterization of monoclonal antibodies using Microfluidic Modulation Spectroscopy","volume":"646","author":"Ivancic","year":"2022","journal-title":"Anal. Biochem."},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb1180","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1389203003381315","article-title":"The use of circular dichroism in the investigation of protein structure and function","volume":"1","author":"Kelly","year":"2000","journal-title":"Curr. Protein Pept. Sci."},{"issue":"1, Part A","key":"10.1016\/j.addr.2026.115793_bb1185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbamem.2013.06.019","article-title":"Ligand- and drug-binding studies of membrane proteins revealed through circular dichroism spectroscopy","volume":"1838","author":"Siligardi","year":"2014","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.addr.2026.115793_bb1190","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpba.2014.04.011","article-title":"Theory and practice of size exclusion chromatography for the analysis of protein aggregates","volume":"101","author":"Fekete","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"20","key":"10.1016\/j.addr.2026.115793_bb1195","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1080\/10826076.2012.743724","article-title":"Size-Exclusion Chromatography for the Analysis of Protein Biotherapeutics and their Aggregates","volume":"35","author":"Hong","year":"2012","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb1200","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103848","article-title":"Effect of silicone oil on the structure, stability, and aggregation of a therapeutic antibody","volume":"114","author":"Upadhyay","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115793_bb1205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2021.02.007","article-title":"Understanding molecular mechanisms of biologics drug delivery and stability from NMR spectroscopy","volume":"174","author":"Phyo","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.addr.2026.115793_bb1215","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1021\/acs.molpharmaceut.3c00764","article-title":"Solid-State NMR Spectroscopy to Probe State and Phase Transitions in Frozen Solutions","volume":"20","author":"Du","year":"2023","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.addr.2026.115793_bb1220","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.xphs.2024.11.017","article-title":"Molecular mechanisms for stabilizing biologics in the solid state","volume":"114","author":"Ling","year":"2025","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb1225","doi-asserted-by":"crossref","first-page":"2304624","DOI":"10.1080\/19420862.2024.2304624","article-title":"In-situ biophysical characterization of high-concentration protein formulations using w NMR","volume":"16","author":"Song","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115793_bb1240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114830","article-title":"Non-invasive detection of protein aggregation in biopharmaceuticals using TD-NMR and MRI","volume":"215","author":"Ozesme Taylan","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2026.115793_bib1496","doi-asserted-by":"crossref","first-page":"115779","DOI":"10.1016\/j.addr.2026.115779","article-title":"Optical imaging and spectroscopic characterization of subvisible particles in protein therapeutics","volume":"230","author":"Wong","year":"2026","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb1245","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1208\/s12248-010-9233-x","article-title":"Characterization of particles in protein solutions: reaching the limits of current technologies","volume":"12","author":"Demeule","year":"2010","journal-title":"AAPS J."},{"issue":"9","key":"10.1016\/j.addr.2026.115793_bb1250","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/jps.20347","article-title":"Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution","volume":"94","author":"Liu","year":"2005","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb1255","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-010-9205-1","article-title":"Micro-flow imaging: flow microscopy applied to sub-visible particulate analysis in protein formulations","volume":"12","author":"Sharma","year":"2010","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb1230","article-title":"Effects of temperature and relative humidity in D2O on solid-state hydrogen deuterium exchange mass spectrometry (ssHDX-MS)","volume":"596","author":"Tukra","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb0265","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1208\/s12248-013-9485-3","article-title":"Non-Arrhenius Protein Aggregation","volume":"15","author":"Wang","year":"2013","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb0270","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2044744","article-title":"Computational models for studying physical instabilities in high concentration biotherapeutic formulations","volume":"14","author":"Blanco","year":"2022","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115793_bb1285","article-title":"Biophysical Characterization of Biopharmaceutical Products","author":"Su","year":"2018","journal-title":"American Association of Pharmaceutical Scientists Newsmagazine"},{"issue":"7","key":"10.1016\/j.addr.2026.115793_bb1290","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41594-019-0238-6","article-title":"The peptide hormone glucagon forms amyloid fibrils with two coexisting beta-strand conformations","volume":"26","author":"Gelenter","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb1295","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.xphs.2019.11.001","article-title":"Protein-Protein Interactions, Clustering, and Rheology for Bovine IgG up to High Concentrations Characterized by Small Angle X-Ray Scattering and Molecular Dynamics Simulations","volume":"109","author":"Chowdhury","year":"2020","journal-title":"J. Pharm. Sci. USA"},{"issue":"10","key":"10.1016\/j.addr.2026.115793_bb1300","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1021\/acs.molpharmaceut.9b00687","article-title":"Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering","volume":"16","author":"Xu","year":"2019","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.addr.2026.115793_bb1305","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1021\/acs.molpharmaceut.0c00554","article-title":"Probing Protein Conformation Destabilization in Sterile Liquid Formulations through the Formation of 3,4-Dihydroxyphenylalanine","volume":"17","author":"Mozziconacci","year":"2020","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb1310","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2124902","article-title":"Investigating protein-excipient interactions of a multivalent V(HH) therapeutic protein using NMR spectroscopy","volume":"14","author":"Panchal","year":"2022","journal-title":"MAbs"},{"issue":"26","key":"10.1016\/j.addr.2026.115793_bb1315","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1007\/s00216-014-7924-3","article-title":"Higher order structure characterization of protein therapeutics by hydrogen\/deuterium exchange mass spectrometry","volume":"406","author":"Huang","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.addr.2026.115793_bb1320","series-title":"M. Effects of temperature and relative humidity in D","author":"Tukra","year":"2026"},{"issue":"7","key":"10.1016\/j.addr.2026.115793_bb1335","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1021\/acs.molpharmaceut.1c00189","article-title":"Understanding the Impact of Protein-Excipient Interactions on Physical Stability of Spray-Dried Protein Solids","volume":"18","author":"Chen","year":"2021","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb1340","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1021\/acs.molpharmaceut.4c01488","article-title":"Impact of Sugar Molecular Weight on the Miscibility and Stability of Lyophilized and Spray-Dried Protein Formulations","volume":"22","author":"Nguyen","year":"2025","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb1345","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s11095-022-03318-7","article-title":"Effect of Buffer Salts on Physical Stability of Lyophilized and Spray-Dried Protein Formulations Containing Bovine Serum Albumin and Trehalose","volume":"40","author":"Mutukuri","year":"2023","journal-title":"Pharm. Res."},{"issue":"1\u20132","key":"10.1016\/j.addr.2026.115793_bb1350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.03.041","article-title":"Nature and consequences of protein-protein interactions in high protein concentration solutions","volume":"358","author":"Saluja","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.addr.2026.115793_bb1355","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/19420862.2019.1589850","article-title":"Hydrogen\/deuterium exchange-mass spectrometry analysis of high concentration biotherapeutics: application to phase-separated antibody formulations","volume":"11","author":"Tian","year":"2019","journal-title":"Mabs"},{"key":"10.1016\/j.addr.2026.115793_bb1360","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejpb.2021.01.014","article-title":"Powder suspensions in non-aqueous vehicles for delivery of therapeutic proteins","volume":"161","author":"Marschall","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"12","key":"10.1016\/j.addr.2026.115793_bb1365","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1002\/jps.23324","article-title":"Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection","volume":"101","author":"Bowen","year":"2012","journal-title":"J. Pharm. Sci. USA"},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb1370","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1021\/acs.molpharmaceut.2c00039","article-title":"Spray-Dried Monoclonal Antibody Suspension for High-Concentration and Low-Viscosity Subcutaneous Injection","volume":"19","author":"Huang","year":"2022","journal-title":"Mol. Pharm."},{"issue":"812","key":"10.1016\/j.addr.2026.115793_bb1375","doi-asserted-by":"crossref","first-page":"eadv6427","DOI":"10.1126\/scitranslmed.adv6427","article-title":"Ultrahigh-concentration biologic therapeutics enabled by spray drying with a glassy surfactant excipient","volume":"17","author":"Jons","year":"2025","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb1380","first-page":"202","article-title":"S.C. delivery of ultra-high concentration (up to 500 mg\/mL) protein microparticle suspensions: pharmacokinetics, efficacy, biodistribution, and immunogenicity. Drug Deliv","volume":"16","author":"Shadbar","year":"2026","journal-title":"Transl. Res."},{"key":"10.1016\/j.addr.2026.115793_bb1385","article-title":"S. High-Concentration Antibody Formulation via Solvent-Based Dehydration","author":"Zheng","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2026.115793_bb1390","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.4c01488","article-title":"Impact of Sugar Molecular Weight on the Miscibility and Stability of Lyophilized and Spray-Dried Protein Formulations","author":"Nguyen","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115793_bb1395","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2020.116152","article-title":"Solid-state NMR spectroscopy in pharmaceutical sciences","volume":"135","author":"Li","year":"2021","journal-title":"Trac-Trend. Anal. Chem."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb1405","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.xphs.2020.11.017","article-title":"Probing Microenvironmental Acidity in Lyophilized Protein and Vaccine Formulations Using Solid-state NMR Spectroscopy","volume":"110","author":"Li","year":"2021","journal-title":"J. Pharm. Sci. USA"},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb1410","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1208\/s12248-016-9937-7","article-title":"Influence of Miscibility of Protein-Sugar Lyophilizates on Their Storage Stability","volume":"18","author":"Mensink","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115793_bb1415","series-title":"Utilizing Solid-State NMR Spectroscopy to Assess Properties of Lyophilized Formulations","author":"Lay-Fortenbery","year":"2022"},{"issue":"6","key":"10.1016\/j.addr.2026.115793_bb1420","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s11095-022-03438-0","article-title":"Convolutional Neural Networks Enable Highly Accurate and Automated Subvisible Particulate Classification of Biopharmaceuticals","volume":"40","author":"Wang","year":"2023","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.addr.2026.115793_bb1425","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.xphs.2019.05.018","article-title":"Characterization of Protein Aggregates, Silicone Oil Droplets, and Protein-Silicone Interactions Using Imaging Flow Cytometry","volume":"109","author":"Probst","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.addr.2026.115793_bb1430","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.xphs.2020.10.022","article-title":"Characterization of Aggregated Antibody-Silicone Oil Complexes: From Perspectives of Morphology, 3D Image, and Fcgamma Receptor Activation","volume":"110","author":"Kiyoshi","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.addr.2026.115793_bb1435","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1021\/acs.molpharmaceut.3c00391","article-title":"Characterizing Silicone Oil-Induced Protein Aggregation with Stimulated Raman Scattering Imaging","volume":"20","author":"Wong","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115793_bb1440","first-page":"648","article-title":"Reversible protein complexes as a promising avenue for the development of high concentration formulations of biologics","author":"Dahmana","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"22","key":"10.1016\/j.addr.2026.115793_bb1450","doi-asserted-by":"crossref","first-page":"8469","DOI":"10.1021\/acs.analchem.2c05485","article-title":"Combined Liquid-State and Solid-State Nuclear Magnetic Resonance at Natural Abundance for Comparative Higher Order Structure Assessment in the Formulated-State of Biphasic Biopharmaceutics","volume":"95","author":"Pujahari","year":"2023","journal-title":"Anal. Chem."},{"issue":"27","key":"10.1016\/j.addr.2026.115793_bb1455","doi-asserted-by":"crossref","first-page":"14290","DOI":"10.1021\/acs.analchem.5c01073","article-title":"Enabling Liquid Scanning Electron Microscopy for Therapeutic Suspensions Using Vacuum-Compatible Liquid Capsules","volume":"97","author":"Borum","year":"2025","journal-title":"Anal. Chem."},{"issue":"10","key":"10.1016\/j.addr.2026.115793_bb1465","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1021\/acs.analchem.7b00464","article-title":"Water Proton NMR: A Tool for Protein Aggregation Characterization","volume":"89","author":"Taraban","year":"2017","journal-title":"Anal. Chem."},{"key":"10.1016\/j.addr.2026.115793_bb1460","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2304624","article-title":"In-situ Biophysical Characterization of High Concentration Protein Formulations Using wNMR","author":"Song","year":"2024","journal-title":"mAbs"},{"issue":"7","key":"10.1016\/j.addr.2026.115793_bb1470","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.xphs.2016.04.015","article-title":"Aggregation and Particle Formation of Therapeutic Proteins in Contact With a Novel Fluoropolymer Surface Versus Siliconized Surfaces: Effects of Agitation in Vials and in Prefilled Syringes","volume":"105","author":"Teska","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115793_bb1475","article-title":"Design of a Reciprocal Injection Device for Stability Studies of Parenteral Biological Drug Products","author":"Du","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"18","key":"10.1016\/j.addr.2026.115793_bb1480","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1073\/pnas.1702724114","article-title":"Inducing protein aggregation by extensional flow","volume":"114","author":"Dobson","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.addr.2026.115793_bb1485","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/bit.26543","article-title":"Using extensional flow to reveal diverse aggregation landscapes for three IgG1 molecules","volume":"115","author":"Willis","year":"2018","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2026.115793_bb1490","article-title":"Exploring a role for flow-induced aggregation assays in platform formulation optimisation for antibody-based proteins","author":"Willis","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.addr.2026.115793_bb1495","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1021\/acs.molpharmaceut.4c00544","article-title":"Industrial Horizons in Pharmaceutical Science","volume":"21","author":"Brader","year":"2024","journal-title":"Mol. Pharm."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X2600027X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X2600027X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T08:29:21Z","timestamp":1779006561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X2600027X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":289,"alternative-id":["S0169409X2600027X"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115793","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High concentration subcutaneous biological drug products: challenges and advancements","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115793"}}